Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2013;4(1):35-48.
Epub 2013 Mar 18.

Variants in tamoxifen metabolizing genes: a case-control study of contralateral breast cancer risk in the WECARE study

Jennifer D Brooks  1 , Sharon N Teraoka, Kathleen E Malone, Robert W Haile, Leslie Bernstein, Charles F Lynch, Lene Mellemkjær, David J Duggan, Anne S Reiner, Patrick Concannon, Katherine Schiermeyer, Juan Pablo Lewinger; WECARE Study Collaborative Group; Jonine L Bernstein, Jane C Figueiredo
Affiliations

Variants in tamoxifen metabolizing genes: a case-control study of contralateral breast cancer risk in the WECARE study

Jennifer D Brooks et al. Int J Mol Epidemiol Genet. 2013.

Abstract

Tamoxifen has been shown to greatly reduce risk of recurrence and contralateral breast cancer (CBC). Still, second primary contralateral breast cancer is the most common malignancy to follow a first primary breast cancer. Genetic variants in CYP2D6 and other drug-metabolizing enzymes that alter the metabolism of tamoxifen may be associated with CBC risk in women who receive the drug. This is the first study to investigate the impact of this variation on risk of CBC in women who receive tamoxifen. From the population-based Women's Environment Cancer and Radiation Epidemiology (WECARE) Study, we included 624 Caucasian women with CBC (cases) and 1,199 women with unilateral breast cancer (controls) with complete information on tumor characteristics and treatment. Conditional logistic regression was used to assess the risk of CBC associated with 112 single nucleotide polymorphisms (SNPs) in 8 genes involved in the metabolism of tamoxifen among tamoxifen users and non-users. After adjustment for multiple testing, no significant association was observed between any of the genotyped variants and CBC risk in either tamoxifen users or non-users. These results suggest that when using a tagSNP approach, common variants in selected genes involved in the metabolism of tamoxifen are not associated with risk of CBC among women treated with the drug.

Keywords: Contralateral breast cancer; single nucleotide polymorphisms; tamoxifen.

PubMed Disclaimer

References

    1. Early Breast Cancer Trialists’ Collaborative Group. Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet. 2005;365:1687–1717. - PubMed
    1. Cook LS, Weiss NS, Schwartz SM, White E, McKnight B, Moore DE, Daling JR. Population-Based Study of Tamoxifen Therapy and Subsequent Ovarian, Endometrial, and Breast Cancers. J Natl Cancer Inst. 1995;87:1359–1364. - PubMed
    1. Gajalakshmi CK, Shanta V, Hakama M. Risk factors for contralateral breast cancer in Chennai (Madras), India. Int J Epidemiol. 1998;27:743–750. - PubMed
    1. Li CI, Malone KE, Weiss NS, Daling JR. Tamoxifen Therapy for Primary Breast Cancer and Risk of Contralateral Breast Cancer. J Natl Cancer Inst. 2001;93:1008–1013. - PubMed
    1. Bertelsen L, Bernstein L, Olsen JH, Mellemkjaer L, Haile RW, Lynch CF, Malone KE, Anton-Culver H, Christensen J, Langholz B, Thomas DC, Begg CB, Capanu M, Ejlertsen B, Stovall M, Boice JD Jr, Shore RE, Bernstein JL Women’s Environment, Cancer and Radiation Epidemiology Study Collaborative Group. Effect of Systemic Adjuvant Treatment on Risk for Contralateral Breast Cancer in the Women’s Environment, Cancer and Radiation Epidemiology Study. J Natl Cancer Inst. 2008;100:32–40. - PubMed

LinkOut - more resources